Lexaria Bioscience Corp. financial data

Symbol
LEXX, LEXXW on Nasdaq
Location
Kelowna, British Columbia, Canada
Fiscal year end
31 August
Latest financial report
10-Q - Q4 2025 - 13 Jan 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 357% % -81%
Debt-to-equity 32% % 429%
Return On Equity -227% % -155%
Return On Assets -168% % -101%
Operating Margin -2062% % -40%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24,887,446 shares 42%
Common Stock, Shares, Outstanding 22,225,846 shares 27%
Common Stock, Value, Issued $22,226 USD 27%
Weighted Average Number of Shares Outstanding, Diluted 21,376,029 shares 28%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $522,000 USD 5%
Research and Development Expense $6,956,877 USD 86%
General and Administrative Expense $4,328,784 USD 6.6%
Operating Income (Loss) $10,763,661 USD -47%
Nonoperating Income (Expense) $36,857 USD -39%
Income Tax Expense (Benefit) $1,791 USD
Net Income (Loss) Attributable to Parent $10,793,149 USD -47%
Earnings Per Share, Diluted -0.57 USD/shares -14%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,300,000 USD
Marketable Securities, Current $0 USD -100%
Accounts Receivable, after Allowance for Credit Loss, Current $88,044 USD -67%
Assets, Current $5,363,129 USD -39%
Property, Plant and Equipment, Net $216,120 USD -20%
Assets $6,050,807 USD -38%
Liabilities, Current $1,456,534 USD 389%
Operating Lease, Liability, Noncurrent $70,819 USD -31%
Liabilities $1,527,353 USD 282%
Accumulated Other Comprehensive Income (Loss), Net of Tax $76,079 USD -231%
Retained Earnings (Accumulated Deficit) $65,055,620 USD -20%
Stockholders' Equity Attributable to Parent $4,912,892 USD -50%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4,523,454 USD -52%
Liabilities and Equity $6,050,807 USD -38%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $984,098 USD 64%
Net Cash Provided by (Used in) Financing Activities $3,474,051 USD -20%
Net Cash Provided by (Used in) Investing Activities $5,099 USD 87%
Common Stock, Shares Authorized 220,000,000 shares 0%
Common Stock, Shares, Issued 22,225,846 shares 27%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,479,110 USD 57%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,281,233 USD -47%
Operating Lease, Liability $101,920 USD
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $10,846,237 USD -48%
Operating Lease, Liability, Current $31,101 USD 7.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two $38,642 USD 38%
Lessee, Operating Lease, Liability, to be Paid, Year One $28,009 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $38,900 USD 4.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four $8,104 USD -79%
Additional Paid in Capital $70,022,365 USD 9.3%
Amortization of Intangible Assets $4,857 USD
Depreciation, Depletion and Amortization $12,009 USD 37%
Share-based Payment Arrangement, Expense $74,895 USD -25%